

**I. Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-17. (cancelled)

Claim 18. (previously presented) A method for producing an immune response in humans, said method comprising the steps of:

(a) inserting a suppository into a urogenital orifice of a human, wherein said suppository comprises a vaccine or vaccine adjuvant(s) of microbial pathogens, capable of producing humoral or cellular-mediated immunity against urogenital disease in humans and a suppository base, wherein the suppository base comprises about 98% of polyethylene glycol and about 2% of polysorbate; and

(b) contacting the suppository with mucosal tissue at and internal to the urogenital orifice to facilitate transfer of the vaccine or vaccine adjuvant material therethrough and induce an immune response in the human.

Claims 19-21 (cancelled)

Claim 22. (previously presented) The method of claim 18, wherein said suppository further comprises thimersol as a preservative.

Claims 23-25. (cancelled)

Claim 26. (previously presented) The method of claim 18, wherein said urogenital orifice is a vagina.

Claim 27-31 (cancelled)

287.1003CIP

Claim 32. (previously presented) The method of claim 18, wherein said urogenital disease is a urinary tract infection.

Claim 33-36. (cancelled)